ArticleIDCases2025
Tailored management of chronic bacterial prostatitis with sequential fluoroquinolones and adverse effect mitigation strategies: A case report.
Article in IDCases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic bacterial prostatitis (CBP) presents diagnostic and therapeutic challenges, particularly in patients with drug allergies and atypical symptom profiles. This case describes a retired male healthcare professional with exclusive penile pain and urinary symptoms, diagnosed with CBP. Management involved sequential fluoroquinolone therapy-ciprofloxacin followed by moxifloxacin-over 6.5 weeks, guided by clinical condition and pharmacokinetic/ pharmacodynamic (PK/PD) considerations. To mitigate adverse drug reaction (ADR) risks, the patient incorporated probiotics, tendon support measures, and QT monitoring. The individualized approach resulted in significant symptomatic improvement without complications. Follow-up focused on prostate-specific antigen (PSA) monitoring, symptom tracking, and referral to pelvic floor physical therapy. This case's approach combining sequential fluoroquinolone therapy with structured ADR-prevention strategies and a patient-engaged, shared decision-making model underscores the importance of individualized, multidisciplinary care in CBP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.